AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00840216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN® XL 500 mg tablets
Description: 1 x 500 mg
Study NCT04264585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Session
Description: Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered).
Study NCT03110835 — intervention group
Intervention type: RADIATION
Intervention: Radioiodine
Description: Administration of radioiodine
Study NCT00286455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
Study NCT00286455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
Study NCT00286455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Study NCT03827642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study NCT00840073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg Tablets
Description: 1 x 4 mg, single-dose fed
Study NCT00840073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik® 4 mg Tablets
Description: 1 x 4 mg, single-dose fed
Study NCT00218257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200mg progesterone twice daily
Study NCT00218257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01370369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 99903)
Study NCT04234334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consume 2 eggs with spinach per day
Description: Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
Study NCT04234334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Subsitute with spinach per day
Description: Egg Subsitute with spinach per day
Study NCT03323008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prototype
Description: Usability testing and System Usability Scale
Study NCT01838941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time).
Study NCT00144014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V10153
Description: Single acute intravenous bolus dose up to 10 mg/kg
Study NCT02321098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL + Cosmetic varnish
Description: Loceryl NL + Cosmetic varnish once/week for 12 weeks
Study NCT02321098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL 12 weeks
Description: Loceryl NL once/week for 12 weeks
Study NCT02321098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL 15 months
Description: Loceryl once/week for additional 15 months
Study NCT03084250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2A
Description: 180μg/week, 48 weeks; 135μg/week,48weeks
Study NCT03084250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir, entecavir,tenofovir, either of them
Description: Adefovir, entecavir,tenofovir, either of them is ok
Study NCT01124305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Patient Instrumentation
Description: Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
Study NCT01124305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Instrumentation
Description: Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
Study NCT02979522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin infusion
Study NCT02979522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion
Study NCT02979522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine infusion
Study NCT02979522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine infusion
Study NCT03827642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study NCT03827642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCl Intravenous (IV) Injection
Description: Participants received naloxone HCl IV injection following a 10 hour fast.
Study NCT03827642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.
Study NCT02032784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: Octreotide 100mg subcutaneous every 8 hours for 5 days
Study NCT02032784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Octreotide
Description: No drug
Study NCT03738215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules
Study NCT03738215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied in capsules
Study NCT03157791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 180Mg Cap
Description: Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
Study NCT02148627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658 (SC)
Description: Administered SC
Study NCT02148627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658 (IV)
Description: Administered as slow IV infusion
Study NCT02148627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as slow IV infusion
Study NCT03042637 — intervention group
Intervention type: DRUG
Intervention: Acthar Gel and Tacrolimus
Description: Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
Study NCT01033071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study NCT01033071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study NCT01033071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil and hydrochlorothiazide
Description: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study NCT03208452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Study NCT03208452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Study NCT00575302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f®: follitropin alpha
Description: Gonal-f®: follitropin alpha, administration of 300 U
Study NCT00575302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f®: follitropin alpha
Description: Gonal-f®: follitropin alpha, administration of 450 U
Study NCT04363814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bactek-R
Description: BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
Study NCT00652132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00652132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00652132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Study NCT00084253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/ Stavidine / Lamivudine
Description: Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
Study NCT00084253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir-Ritonavir/ Stavidine / Lamivudine
Description: Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram, 10mg to 20mg daily.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram, 10mg to 20mg daily.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil, 5mg to 10mg daily.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine, 150mg to 300mg daily.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine, 150mg to 300mg daily.
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT00177671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Study NCT03947034 — intervention group
Intervention type: DRUG
Intervention: Drugs inducing hyperammonemia
Description: Drugs susceptible to induce metabolic toxicities such as hyperammonemia
Study NCT01765491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose polyethylene glycol
Description: Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
Study NCT01765491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning-only polyethylene glycol
Description: One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
Study NCT01331902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Hyperemia with Adenosine Followed by Nicorandil
Description: Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
Study NCT01331902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Hyperemia with Nicorandil Followed by Adenosine
Description: Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
Study NCT03247114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature
Study NCT03247114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature
Study NCT03033498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.
Study NCT00787254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
Study NCT00787254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefarnate
Description: Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
Study NCT03557541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sardine
Description: They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
Study NCT03557541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: They received a common T2D-preventive diet
Study NCT04306783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-home sensor monitoring
Description: -Installed and maintained by Foresite Healthcare
Study NCT02186691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02649179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
Study NCT02649179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
Study NCT01017926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam
Description: Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
Study NCT01017926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
Study NCT03666026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 MyChart R/R
Description: Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
Study NCT03666026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 MyChart R/R
Description: Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
Study NCT03666026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 MyChart R/R
Description: Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
Study NCT03444090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon polypectomy
Description: For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
Study NCT03444090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon polypectomy
Description: For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
Study NCT02598089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Seasonal Influenza Vaccine
Study NCT02598089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of phosphate buffered saline
Study NCT01612091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Messenger
Description: Monitoring Messenger prototype device
Study NCT01612091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional tools
Description: Paper based records, screenshots of monitors and therapy devices
Study NCT00308152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 1 litre of normal saline before colonoscopy
Description: Prehydration with normal saline
Study NCT02060747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinator-based post fracture program
Study NCT06560814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline plus timed intercourse
Description: Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
Study NCT06560814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone plus timed intercourse
Description: Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
Study NCT02181647 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Touches: Personal Safety Training for Children
Description: The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
Study NCT02181647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Touches: Personal Safety Training for Children
Description: The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
Study NCT01188681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-016 and bendamustine
Description: TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
Study NCT01188681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles